Paratek Pharmaceuticals Inc. Daily Stock Analysis

Daily Stock Analysis, PRTK, Paratek Pharmaceuticals Inc, priceseries

Paratek Pharmaceuticals Inc. Daily Stock Analysis
Stock Information
Open
3.32
Close
3.38
High
3.38
Low
3.23
Previous Close
3.35
Daily Price Gain
0.03
YTD High
4.80
YTD High Date
Jan 11, 2022
YTD Low
3.23
YTD Low Date
Mar 7, 2022
YTD Price Change
-1.22
YTD Gain
-26.52%
52 Week High
11.24
52 Week High Date
Jun 10, 2021
52 Week Low
3.23
52 Week Low Date
Mar 7, 2022
52 Week Price Change
-3.81
52 Week Gain
-52.99%
Recent priceSeries Trade Signals

These are sample algorithmic trades based on actual market data.

Trade Type
Entry Date
Entry Price
Exit Date
Exit Price
Trade Hold Time
Gain
Trade Record
LONG
Dec 23. 2016
14.20
Jan 11. 2017
15.39
11 Trading Days
8.39%
Link
LONG
Mar 28. 2017
17.55
Apr 18. 2017
21.53
14 Trading Days
22.65%
Link
LONG
Jun 16. 2017
22.50
Jun 30. 2017
24.28
10 Trading Days
7.93%
Link
LONG
Jan 2. 2019
5.57
Jan 28. 2019
6.51
17 Trading Days
16.91%
Link
LONG
Sep 6. 2019
3.89
Sep 17. 2019
4.70
7 Trading Days
20.93%
Link
LONG
Apr 3. 2020
3.21
Apr 30. 2020
4.24
18 Trading Days
32.24%
Link
LONG
May 29. 2020
4.44
Jun 10. 2020
4.74
8 Trading Days
6.85%
Link
LONG
Sep 9. 2020
4.65
Sep 23. 2020
5.78
10 Trading Days
24.22%
Link
LONG
Nov 4. 2020
4.93
Dec 14. 2020
6.64
27 Trading Days
34.63%
Link
LONG
Feb 2. 2021
6.74
Feb 11. 2021
7.52
7 Trading Days
11.63%
Link
Company Information
Stock Symbol
PRTK
Exchange
NasdaqGM
Company URL
http://paratekpharma.com
Company Phone
(617) 807-6600
CEO
Michael F. Bigham
Headquarters
Massachusetts
Business Address
75 PARK PLAZA, 4TH FLOOR, BOSTON, MA 02116
Sector
Equity
Industry Category
Drugs
Industry Group
Biotechnology
CIK
0001178711
About

Paratek Pharmaceuticals, Inc. is a biopharmaceutical company focused on the development and commercialization of innovative therapies based upon its expertise in novel tetracycline chemistry. Its products include Omadacycline and Sarecycline. The company was founded in February 2001 and is headquartered in Boston, MA.

Description

Paratek Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of therapeutics based upon tetracycline chemistry in the United States. Its lead product candidates include omadacycline, a broad-spectrum, intravenous, and oral antibiotic, which is in Phase III clinical stage for use as a monotherapy antibiotic for acute bacterial skin and skin structure infections (ABSSSI), community-acquired bacterial pneumonia (CABP), urinary tract infections, and other community-acquired bacterial infections; and Sarecycline, a tetracycline-derived compound that is in Phase III clinical trial for the treatment of acne and rosacea. The company has special protocol assessment agreements with Food and Drug Administration for the Phase III studies for ABSSSI and CABP. It has collaborative research and license agreement with Allergan plc to research, develop, and commercialize tetracycline products; license agreement with Tufts University to develop and commercialize products for the treatment or prevention of bacterial or microbial diseases, or medical conditions; and license agreement with Shin Nippon Biomedical Laboratories Ltd. to develop TO-2070 for the treatment of acute migraine. The company also has a cooperative research and development agreement with the U.S. Army Medical Research Institute of Infectious Diseases to study omadacycline against pathogenic agents causing infectious diseases. Paratek Pharmaceuticals, Inc. was founded in 1996 and is headquartered in Boston, Massachusetts.

TCHANNELS® is a Registered Trademark with USPTO

Some images used on this site have been taken from Unsplash

Legal Information

Useful Links

Contact Us

PO Box 2574, Sunnyvale
California 94087-0574, USA
Phone: 408-940-5056
Email: Click to send us an Email

Risks of Algorithmic Trading: Before investing please read our disclosure on Risks of Algorithmic Trading.

DISCLAIMER All investments entail inherent risk. This research seeks to assist investors in determining when to buy and when to sell to attempt to maximize profits or minimize losses. All final investment decisions are yours and as a result you could make or lose money. priceSeries.com, its employees and/or its affiliates and family members may from time to time take positions in the open market or otherwise with respect to the securities discussed. priceSeries.com, its employees and/or affiliates do not have stock ownership equal to or greater than 1% of the outstanding stock of the covered company nor does any employee of priceSeries.com sit on the Board of Directors of any covered company. priceSeries.com is not a broker/dealer, and the firm does not underwrite securities, manage assets or perform investment banking activities. The statements made herein include information obtained from sources believed to be reliable, but no independent verification has been made and we do not guarantee its accuracy or completeness.

U.S. Government Required Disclaimer - Commodity Futures Trading Commission
Futures and Options trading has large potential rewards, but also large potential risk. You must be aware of the risks and be willing to accept them in order to invest in the futures and options markets. Don't trade with money you can't afford to lose. This is neither a solicitation nor an offer to Buy/Sell futures or options. No representation is being made that any account will or is likely to achieve profits or losses similar to those discussed on this web site. The past performance of any trading system or methodology is not necessarily indicative of future results.

CFTC RULE 4.41 - HYPOTHETICAL OR SIMULATED PERFORMANCE RESULTS HAVE CERTAIN LIMITATIONS. UNLIKE AN ACTUAL PERFORMANCE RECORD, SIMULATED RESULTS DO NOT REPRESENT ACTUAL TRADING. ALSO, SINCE THE TRADES HAVE NOT BEEN EXECUTED, THE RESULTS MAY HAVE UNDER-OR-OVER COMPENSATED FOR THE IMPACT, IF ANY, OF CERTAIN MARKET FACTORS, SUCH AS LACK OF LIQUIDITY. SIMULATED TRADING PROGRAMS IN GENERAL ARE ALSO SUBJECT TO THE FACT THAT THEY ARE DESIGNED WITH THE BENEFIT OF HINDSIGHT. NO REPRESENTATION IS BEING MADE THAT ANY ACCOUNT WILL OR IS LIKELY TO ACHIEVE PROFIT OR LOSSES SIMILAR TO THOSE SHOWN.

2016 © priceSeries.com All Rights Reserved. Privacy Policy | Subscriber Agreement | Risks of Algorithmic Trading